A Laboratory Evaluation of Chromogenic Screening Media for the Detection of **Extended-Spectrum Beta-Lactamase-Producing Bacteria**

Alistair Brown, Simone O'Brien, Steff Cocks, James Beaves and Stephen Dimmer

Thermo Fisher Scientific, Basingstoke, UK

Overview

Purpose: To examine the performance of Thermo Scientific[™] Oxoid[™] Brilliance[™] ESBL Agar (Thermo Fisher Scientific) for the detection of ESBL-producing bacteria in comparison with chromID[®] ESBL (bioMérieux).

Methods: Eighty pure culture isolates, comprising 23 ESBLs, 13 chromosomal AmpC and 44 other non-ESBL producing organisms (including Gram-negative and Grampositive isolates) were prepared as 0.5 McFarland suspensions. Each ESBL was serially diluted and spread over the surface of the medium. Non-ESBL organisms were inoculated directly from the 0.5 McFarland suspensions with a 10µL loop, using the diminishing sweep technique. All plates were incubated aerobically at 37°C for 24 hours.

Results

Both media obtained sensitivity and specificity of >90% in this study (Table 1). Two *E. coli* ESBL isolates (SHV-2 and TEM-3) were not detected by chromID ESBL and one *Ps.* aeruginosa (PER-1) was not detected by Brilliance ESBL Agar. With regard to false positives, both media allowed growth of *Ps. aeruginosa* possessing OXA-10 and a Klebsiella spp. with derepressed chromosomal AmpC, though growth of this isolate was more prolific on the chromID medium. *Brilliance* ESBL Agar also allowed growth of two Ps. aeruginosa isolates with inducible AmpC, while chromID ESBL allowed growth of an A. baumanii isolate with inducible AmpC, as well as isolates of Ps. putida and B. cepacia.

References

- 1. Bisset L. (2007) ESBL-producing Enterobacteriaceae: controlling the spread of infection. Br. J. Nurs. **16**(13):644-647.
- 2. Paterson D.L. (2006) Resistance in Gram-negative bacteria: Enterobacteriaceae. Am. J. Med., 119(6A), S20-S28.
- 3. Glupczynski Y., Berhin C., Bauraing C. and Bogaerts P. (2007) Evaluation of a new selective chromogenic agar medium for detection of extended-spectrum betalactamase producing Enterobacteriaceae. J. Clin. *Microbiol.* **45**(2):501-5. Epub 2006 Dec 20.

Results: Both media examined in this study achieved high sensitivity and specificity within 24 hours and are suitable for the detection of most of the commonly encountered ESBL types. *Brilliance* ESBL Agar provided marginally better sensitivity and specificity in this study.

Introduction

Since the 1980s, the increasing prevalence of plasmidencoded extended-spectrum beta-lactamases (ESBLs) has been of major concern^{1,2}. Treatment options for infections caused by bacteria possessing such plasmids are limited due to their resistance to beta-lactams, monobactams and cephalosporins. In vivo resistance to aminoglycosides, fluoroquinolones and trimethoprimsulfamethoxazole has also been widely reported, leaving carbapenems as the currently preferred therapeutic option².

The EU-funded Mastering Hospital Antimicrobial Resistance (MOSAR) project is currently conducting a large, multi-site trial to determine the prevalence of ESBL producing bacteria across Europe. The MOSAR project has recognized the benefits of chromogenic media for screening and has selected *Brilliance*[™] ESBL Agar for their study. Routine screening for ESBL-producing Enterobacteriaceae using culture on chromogenic media is becoming more widely adopted.

The aim of this study was to examine the performance of Brilliance ESBL Agar, a new chromogenic screening medium for the detection of ESBL-producing bacteria, in comparison with chromID ESBL.

TABLE 1. Sensitivity and specificity of *Brilliance* ESBL Agar and chromID ESBL following aerobic incubation at 37°C for 24 hours.

n=80	Sensitivity	Specificity
<i>Brilliance</i> ESBL Agar	95.7% (22/23)	93.0% (53/57)
chromID ESBL	91.3% (21/23)	91.2% (52/57)

Each medium also enabled differentiation of *E. coli* and coliforms from other Gram-negative bacteria due to enzymic cleavage of specific chromogenic substrates. chromID ESBL typically produces pink or burgundy colonies for *E. coli* and green colonies for coliforms, while Brilliance ESBL Agar typically produces blue colonies for E. coli and green colonies for coliforms (Figure 1).

4. Réglier-Poupet H., Naas T., Carrer A., Cady A., Adam J.M., N Fortineau *et al.* (2008) Performance of chromID ESBL, a chromogenic medium for detection of Enterobacteriaceae producing extended-spectrum beta-lactamases. J. Med. Microbiol. 57(3):310-5.

Methods

Eighty pure culture isolates, comprising 23 ESBLs (*E. coli,* K. pneumoniae, E. cloacae and Ps. aeruginosa, harbouring CTX-M, TEM, SHV, or PER), 13 chromosomal AmpC (E. coli, Enterobacter spp., Klebsiella spp., Citrobacter spp., S. marcescens, A. baumanii and Ps. aeruginosa, including inducible and derepressed variants) and 44 other non-ESBL producing organisms (including Gram-negative and Gram-positive isolates) were prepared as 0.5 McFarland suspensions.

Each ESBL isolate was serially diluted to provide an inoculum of 10 to 100 cfu from a 50mL volume, which was spread over the surface of each medium. Non-ESBL organisms were inoculated directly from the 0.5 McFarland suspensions with a 10µL loop, using the diminishing sweep technique. All plates were incubated aerobically at 37°C for 24 hours.

FIGURE 1. Typical morphology of colonies of ESBLproducing *E. coli* (blue) and *K. pneumoniae* (green) on **Brilliance ESBL Agar, following aerobic incubation at** 37°C for 24 hours.



Conclusion

Previous studies have demonstrated the advantages of chromogenic screening media over traditional culture media for the presumptive identification of ESBL-producing Enterobacteriaceae^{3,4}. Chromogenic screening media can provide earlier presumptive identification than traditional culture-based methods, thereby reducing time to reporting and enabling infection control teams to implement timely control measures.

Both media examined in this study achieved high sensitivity and specificity within 24 hours and are suitable for the detection of most of the commonly encountered ESBL types. *Brilliance* ESBL Agar provided marginally better sensitivity and specificity in this study. Further studies using routine clinical screening samples are currently being undertaken.

> © 2014 Thermo Fisher Scientific Inc. All rights reserved. chromID is a registered trademark of bioMérieux. All other trademarks are the property of Thermo Fisher Scientific Inc. and its subsidiaries.

This information is not intended to encourage use of these products in any manners that might infringe the intellectual property rights of others.

Folio number LT1307A, 10/2014



A Thermo Fisher Scientific Brand